In its recent market research report about the global hereditary angioedema market, research analysts from Transparency Market Research state that it will exhibit a healthy CAGR of 9.10% for the given forecast period of 2017 to 2025. With such a robust rate of growth, the global hereditary angioedema market will reach a new market valuation of US$3.81 bn by the fall of 2025. The initial valuation of the hereditary angioedema market was at US$1.73 bn recorded in 2016.
Mergers and Acquisitions to Become Common for Leading Market Players
It is projected that the global market for hereditary angioedema will see a rise of several new and emerging players in the next few years of the projection period. The competitive landscape of the market is a consolidated one because of the presence of only handful of leading players. However, as more number of large enterprises engage in the activities of core research and development of angioedema therapeutics, the market is projected to flourish and expand in the coming few years. It is projected that leading players in the market will strive hard to maintain their market dominance and will deploy several aggressive marketing strategies. Since the global hereditary angioedema market is closely associated with the pharmaceutical and medical industries, the leading companies in the market are projected to form strategic partnerships and collaborations with the pharmacies, distributors, and other medical & healthcare bodies. In addition to this, mergers and takeovers are expected to becoming increasingly common as established players will go all out for maintaining their brand value in the global hereditary angioedema market.
Abysmal Effects of Angioderma to Propel Demand
Some of the leading players in the global hereditary angioedema market include names such as BioCryst Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., CSL Limited, Pharming Group NV, and Shire Plc. among others.
North America Market to Lead Global Market for Next Few Years
In terms of geographical segments, the region of North America is expected to dominate the global hereditary angioedema market for the aforementioned forecast period. There are several factors that are helping the regional segment to stay as the chief contributor in the global market. One of the primary driving factors for the growth of the regional market has been growing support and initiatives offered by the government for patients suffering from hereditary angioedema. Moreover, favorable policies for medical reimbursement have also helped in extending the reach of the market. Due to the early access of advanced technology, the instances of early detection of hereditary angioedema are high. This too has helped in the development of the regional segment.
Market Segmentation is as follows:
- C1 Esterase Inhibitor
- Selective Bradykinin B2 Receptor Antagonist
- Kallikrein Inhibitor
Route of Administration
- Subcutaneous Injection
- Retail Pharmacies
- Hospital Pharmacies
- North America
- Latin America
- Asia Pacific
- Middle East and Africa
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Transparency Market Research
90 State Street,
Albany NY - 12207
USA - Canada Toll Free: 866-552-3453
7 of 10 large enterprizes view our ToC to take the right decision.View Report ToC